Second Sight Medical Products Inc. (NASDAQ:EYES) shares rose 6.6% during trading on Friday . The company traded as high as $4.47 and last traded at $4.34, with a volume of 744,948 shares changing hands. The stock had previously closed at $4.07.

Separately, Zacks Investment Research cut Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Monday, April 18th.

The firm’s market cap is $148.83 million. The company’s 50-day moving average price is $3.85 and its 200-day moving average price is $4.49.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings data on Thursday, April 28th. The medical device company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03. The firm earned $1.05 million during the quarter, compared to analyst estimates of $1.38 million. Second Sight Medical Products’s revenue for the quarter was down 38.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.12) EPS. On average, equities analysts anticipate that Second Sight Medical Products Inc. will post ($0.65) EPS for the current fiscal year.

In other news, Chairman Robert J. Greenberg sold 8,571 shares of Second Sight Medical Products stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total transaction of $35,141.10. Following the completion of the sale, the chairman now directly owns 172,911 shares in the company, valued at approximately $708,935.10. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.